Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > COLUMN
COLUMN
- How to Get 4 Qualified Candidates within 4 Weeks
September 25, 2023
- How Far Has Your Organization Come? Key Lessons Learned from Ongoing Commercial Transformations in Japan
September 11, 2023
- Mission Impossible: Finding the Right Leader to Launch a Disruptive Medical Technology into Japan
August 10, 2023
- How Healthcare Companies Should Hire in the Post-COVID Work Environment
July 19, 2023
- The Impact of a Shrinking Labor Market on the Healthcare Industry
June 23, 2023
- Seven Recruitment Trends in 2023
May 31, 2023
- The Inflation Reduction Act - Implications for Japanese Pharmaceutical Manufacturers
May 19, 2023
- How to Serve and Get Ahead
April 21, 2023
- The Increasing Impact of Real-World Evidence
March 31, 2023
- Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
- Why Market Mapping Is Critical to Your Organization
February 24, 2023
- When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
- Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
- How to Succeed in Bad Times and Good
December 9, 2022
- The Pros and Cons of Working from Home in 2022
November 25, 2022
- Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
- The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
- Fairness, Not Diversity
August 26, 2022
- Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
- The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…